UBS Group
BSX.PRA

UBS Group’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

UBS Group’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity
Upgrade to unlock
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
2023
Q1 		$45.4K Sell
2022
Q4 		$47.9K Sell
2022
Q3 		$93K Buy
2022
Q2 		$50K Sell
2022
Q1 		$87K Buy